Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 86.2% to $0.0836 on volume of 666,955,822 shares Airship AI Holdings Inc (AISP) rose 200.0% to $4.95 on volume of 217,603,607 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.6% to $...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 114.7% to $0.0964 on volume of 636,845,097 shares Airship AI Holdings Inc (AISP) rose 194.5% to $4.86 on volume of 190,976,862 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 9.0% to ...
2024-03-05 12:38:40 ET Gainers: Sunshine Biopharma ( SBFM ) +147% . Airship AI Holdings ( AISP ) +87% . Datasea ( DTSS ) +79% . Dave ( DAVE ) +58% . Apogee Therapeutics ( APGE ) +49% . Ocean Biomedical ( OCEA ) +50% ....
2024-03-05 11:33:18 ET More on Quoin Pharmaceuticals Quoin stock soars 60% on FDA update for ichthyosis drug Seeking Alpha’s Quant Rating on Quoin Pharmaceuticals Historical earnings data for Quoin Pharmaceuticals Financial information for Quoin Pharma...
2024-03-05 10:02:11 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
2024-03-05 08:31:33 ET Losers: Quoin Pharmaceuticals Ltd ( QNRX ) -43% announces pricing of $6.5 Million public offering. GigCapital5 ( QTI ) -43% . Gitlab GTLB -23% after Q4 earnings release . SEMrush Holdings SEMR -17% . after Q4 earnings re...
ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the pricing of its "reasonable best efforts" public offering o...
2024-03-04 09:06:31 ET DENVER, Colo., Mar 04, 2024 ( 247marketnews.com )- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX ) reported, this morning, that the U.S. Food and Drug Administration (FDA) cleared the Company to recruit teen subjects aged 14 years and older into its two ongoing cli...
Clearance to include teen patients in both the company’s open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment and lead to a more robust data set This important development represents the first e...
2024-02-12 17:28:31 ET More on Quoin Pharmaceuticals Seeking Alpha’s Quant Rating on Quoin Pharmaceuticals Historical earnings data for Quoin Pharmaceuticals Financial information for Quoin Pharmaceuticals Read the full article on Seeking Alpha ...
News, Short Squeeze, Breakout and More Instantly...
Quoin Pharmaceuticals Ltd. Company Name:
QNRX Stock Symbol:
NASDAQ Market:
Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases UCC’s proprietary dissolvable microneedles technology and other approaches will be utilized to optimize the local delivery ...
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into late 2025 ASHBURN, Va., May 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals...
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty p...